GlassScriptPhysician profile
Isabela Romao
NPI 1639337686
$10,279.57
in general payments reported to CMS, 2019-2025
53 companies · $607 in 2025
The $607 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,216 · 2020: $1,786 · 2021: $2,167 · 2022: $2,588 · 2023: $406 · 2024: $509 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,462 · Long Term Medical Supply Or Device Loan: $59.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,462.48 |
| Long Term Medical Supply Or Device Loan | $59.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $947.69 | 2019-2023 | Repatha |
| Abbott Laboratories | $856.83 | 2019-2025 | Freestyle Libre 3, Freestyle Insulinx |
| Lilly USA, LLC | $854.76 | 2019-2022 | |
| Radius Health, INC. | $692.79 | 2019-2025 | Tymlos |
| Novo Nordisk INC | $589.15 | 2019-2025 | Rybelsus, Ozempic |
| Insulet Corporation | $581.58 | 2019-2024 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $560.89 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $414.72 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Corcept Therapeutics | $378.64 | 2020-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $314.25 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $262.56 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $247.45 | 2019-2022 | |
| Abbvie INC. | $238.96 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $235.01 | 2019-2022 | |
| Recordati_rare_diseases_inc. | $223.49 | 2021-2025 | Isturisa |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isabela Romao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.